Please select your page

Notice of Knight Therapeutics' Third Quarter 2014 Results Conference Call

MONTREAL, CANADA--(Marketwired - Nov. 6, 2014) - Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2014 financial results on Wednesday, November 12, 2014 prior to the market opening. Following the release, Knight will hold a conference call at 8:30 a.m. (EST) hosted by Jonathan Goodman, President and CEO of Knight. Knight cordially invites all interested parties to participate in this call.

CONFERENCE CALL DETAILS:

DATE: Wednesday, November 12, 2014

TIME: 8:30 a.m. EST

DIAL IN NUMBER:1-877-223-4471 OR 647-788-4922

TAPED REPLAY: 1-800-585-8367 OR 416-621-4642

Code: 32217419

Available from Wednesday, November 12, 2014 at 11:30 a.m. until Friday, December 12, 2014 at 11:59 p.m.

About Knight Therapeutics Inc. 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight's shares began trading on TSX-V on March 3, 2014 and graduated to TSX on April 29, 2014 under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's website at http://www.gud-knight.com or at www.sedar.com.

Knight Therapeutics Forward-Looking Statement

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the company's final application for listing on TSX Venture Exchange and in two short form prospectuses which can be found on SEDAR at www.sedar.com, which investors should consult for additional information. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

FOR FURTHER INFORMATION PLEASE CONTACT:

Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-4831
514-481-4116 (FAX)
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.gud-knight.com

 

Buy now

You can now buy this awesome Joomla Theme directly on Themeforest for a really low price for this awesome and stunning Joomla product!

Nulla vitae elit libero, a pharetra augue. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam porta sem malesuada magna mollis euismod. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Nulla vitae elit libero, a pharetra augue.

BUY NOW ON THEMEFOREST

×

Login

Please login using your credentials recived by email when you register.

  or   Create an account

Forgot your password? |  Forgot your username?

×

Register now


I'm a small Introtext for the Register Module, I can be set in the Backend of the Joomla WS-Register Module.



  or   Login
×